Oxigene ( OXGN)

Closing Price: 37 cents (June 29)

Six-Month Stock Performance: -67.8%

Received Nasdaq Notice: June 17

Management's Expected Action: The biopharmaceutical company has until Dec. 14 to regain compliance, which is a tough task as the stock has dropped from a 52-week high of $2.37 all the way to a 52-week low, where it currently rests. Supply-side economist Arthur Laffer resigned from the company's board in March, when the stock still traded above $1. Oxigene shares plunged in early June after the company presented data on clinical studies at the American Society of Clinical Oncology (ASCO) annual meeting. Oxigene said it will "consider various options available to the company if its common stock does not trade at a level that is likely to regain compliance," but didn't offer any specific plans.

If you liked this article you might like

Top Bank Stocks for 2011

Top Bank Stocks for 2011

Bank Watch List Continues to Grow

Bank Watch List Continues to Grow

TARP Deadbeat List Keeps Growing

TARP Deadbeat List Keeps Growing

Regulatory Order Puts Pressure on Anchor

Regulatory Order Puts Pressure on Anchor

Bank Failures Likely to Continue

Bank Failures Likely to Continue